Abstract
Chinese herbal medicine (CHM), as the largest application category of traditional Chinese medicine (TCM), is widely accepted among cancer patients in China. Herbal slice (HS) and Chinese patent drug (CPD) are commonly used CHM in China. This study aimed to investigate the utilization of CHM among clinicians and cancer patients in central China. Five hundred and twenty-five patients and 165 clinicians in 35 comprehensive hospitals in central China were asked to complete an anonymous questionnaire that was designed to evaluate the use of CHM. The results showed that 90.74% clinicians and 72.24% cancer patients used CHM during cancer treatment. The educational backgrounds of the clinicians and the age, education level, annual income, and cancer stage of the cancer patients were related to use of CHM. More than 90% clinicians and cancer patients had used CPD. Comparatively, the percentage of HS use was 10% lower than that of CPD use among clinicians and cancer patients. More clinicians preferred to use CHM after surgery than cancer patients did (20.41% vs. 5.37%). Enhancing physical fitness and improving performance status were regarded as the most potential effect of CHM on cancer treatment (85.71% among clinicians and 94.07% among cancer patients), in comparison with directly killing tumor cells (24.49% among clinicians and 31.36% among patients). As for refusal reasons, imprecise efficacy was the unanimous (100%) reason for clinicians’ rejection of CHM, and 95.58% patients objected to using CHM also for this reason. Furthermore, the side effects of CHM were more concerned by clinicians than by patients (33.33% vs. 15.81%). In conclusion, our survey revealed that CHM was popularly accepted by clinicians and cancer patients in central China. The reasons of use and rejection of CHM were different between clinicians and cancer patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cui Y, Shu XO, Gao Y, et al. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat, 2004,85(3):263–270
Chen Z, Gu K, Zheng Y, et al. The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med, 2008,14(8): 1049–1055
McQuade JL, Meng Z, Chen Z, et al. Utilization of and attitudes towards traditional Chinese medicine therapies in a Chinese cancer hospital: A survey of patients and physicians. Evid Based Complement Alternat Med, 2012,2012:504–507
Ernst E, Cassileth BR. The prevalence of complementary/ alternative medicine in cancer: a systematic review. Cancer, 1998,83(4):777–782
Horneber M, Bueschel G, Dennert G, et al. How many cancer patients use complementary and alternative medicine: a systematic review and meta-analysis. Integr Cancer Ther, 2012,11(3):187–203
Teng L, Jin K, He K, et al. Use of complementary and alternative medicine by cancer patients at Zhejiang University Teaching Hospital Zhuji Hospital, China. Afr J Tradit Complement Altern Med (Chinese), 2010,7(4): 322–330
Pu CY, Lan VM, Lan CF, et al. The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment. Eur J Cancer Care, 2008,17(4):340–349
Liu TG, Xiong SQ, Yan Y, et al. Use of Chinese herb medicine in cancer patients: a survey in southwestern china. Evid Based Complement Alternat Med, 2012, 2012: Article ID:769042,7 pages,2012
Harmsworth K, Lewith GT. Attitudes to traditional Chinese medicine amongst Western trained doctors in the People’s Republic of China. Soc Sci Med, 2001,52(1): 149–153
Chen M. Year Book of Health in the People’s Republic of China, Beijing: RenminWeisheng Pressing, 1997.
Lee RT, Hlubocky FJ, Hu JJ, et al. An international pilot study of oncology physicians’ opinions and practices on complementary and alternative medicine (CAM). Integr Cancer Ther, 2008,7(2):70–75
Lu P, Liang QD, Li R, et al. Effect of traditional Chinese medicine on survival and quality of life in patients with esophageal carcinoma after esophagectomy. Chin J Integr Med (Chinese), 2006,12(3):175–179
Jeong JS, Ryu BH, Kim JS, et al. Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther, 2010,9(4):331–338
Piao BK, Wang YX, Xie GR, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res (Chinese), 2004,24(1):303–309
Loo WT, Jin LJ, Chow LW, et al. Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients. Expert Opin Investig Drugs, 2010,19 (Suppl 1):S91–S100
Dai AW, Li ZY, Wang LH, et al. Effect of Yangyin Humo decoction on oral mucomembranous reaction to radiotherapy. Chin J Integr Med (Chinese), 2009,15(4): 303–306
Li GY, Yu XM, Zhang HW, et al. Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial. Complement Ther Med, 2009,17(2):51–55
Zheng Y. The therapeutic effects of rehmannia oral liquid for the syndrome of heat accumulation with Yin consumption in esophagus cancer patients undergoing radiotherapy—a report of 60 cases. J Tradit Chin Med, 2007,27(4):248–254
Guo Z, Jia X, Liu JP, et al. Herbal medicines for advanced colorectal cancer. Cochrane Database Syst Rev, 2012,5:CD004653
Liu YX, Jiang SJ, Kuang TH, et al. Treatment with yiqibushen koufuye combined with chemotherapy for preventing postoperative metastasis of stomach cancer—a clinical observation of 28 cases. J Tradit Chin Med (Chinese), 2009,29(4):263–267
Zhang L, Wu C, Zhang Y, et al. Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer. J Cell Biochem, 2013,114(9):2131–2137
Tsou YA, Chen KC, Lin HC, et al. Uroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics study. PLoS One, 2012,7(11):e50087
Bao YX, Wong CK, Leung SF, et al. Clinical studies of immunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma. J Altern Complement Med, 2006,12(8):771–776
Guo HY, Cai Y, Yang XM, et al. Randomized phase II trial on mitomycin-C/cisplatin +/-KLT in heavily pretreated advanced breast cancer. Am J Chin Med, 2008,36(4):665–674
Swisher EM, Cohn DE, Goff BA, et al. Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol, 2002,84(3):363–367
Yang YY, Dong Z, Zhu SB, et al. Reevaluation on adverse reaction monitoring and safety of CMMPP of Chongqing from 2005 to 2011. Zhongguo Zhong Yao Za Zhi (Chinese), 2012,37(23):3659–3663
Critchley JA, Zhang Y, Suthisisang CC, et al. Alternative therapies and medical science: designing clinical trials of alternative/complementary medicines is evidence-based traditional Chinese medicine attainable. J Clin Pharmacol, 2000,40(5):462–467
Tian JH, Liu LS, Shi ZM, et al. A randomized controlled pilot trial of “Feiji Recipe” on quality of life of non-small cell lung cancer patients. Am J Chin Med, 2010,38(1): 15–25
Wu WY, Long SQ, Zhang HB, et al. Improvement of quality of life with Shenfu injection in non-small cell lung cancer patients treated with gemcitabine plus cisplatin regimen. Chin J Integr Med (Chinese), 2006,12(1): 50–54
Xu L, Li H, Xu Z, et al. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med, 2012,12:112
Yu Y, Lang Q, Chen Z, et al. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study. Cancer, 2009,115(22):5132–5138
Zhou LY, Shan ZZ, You JL. Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine. Chin J Integr Med (Chinese), 2009,15(2):107–111
Xu ZY, Jin CJ, Zhou CC, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol, 2011,137(7):1117–1122
Guo H, Liu JX, Xu L, et al. Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther, 2011,10(2):127–137
Chen YZ, Li ZD, Gao F, et al. Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer. Chin J Integr Med (Chinese), 2009,15(6):415–419
Zhang Y, Lin HS. Tumor stem cells may be the final target of traditional Chinese medicine in preventing cancer recurrence and metastasis. Zhongguo Zhong Xi Yi Jie He Za Zhi (Chinese), 2009,29(50):461–463
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by Hubei Provincial Health Department Research Fund Project of China (No. 2012Z-Y10).
Rights and permissions
About this article
Cite this article
Chen, G., Qiao, Tt., Ding, H. et al. Use of Chinese herbal medicine therapies in comprehensive hospitals in central China: A parallel survey in cancer patients and clinicians. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 808–814 (2015). https://doi.org/10.1007/s11596-015-1511-5
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-015-1511-5